Previous close | 56.84 |
Open | 56.86 |
Bid | 57.48 x 500000 |
Ask | 58.70 x 500000 |
Day's range | 56.86 - 57.48 |
52-week range | 33.11 - 61.40 |
Volume | |
Avg. volume | 153 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 01 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Protagonist Therapeutics Inc. (NASD: PTGX) will replace Encore Wire Corp. (NASD: WIRE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, July 3. S&P Europe 350 constituent Prysmian SpA (MTAA: PRY) is acquiring Encore Wire in a deal expected to be completed soon pending final conditions.
Attractive options for cash deployment resulting from the Encore-Prysmian merger
Italy's Prysmian aims to reap the benefits from its purchase of Encore Wire faster than initially envisaged, the CEO of the world's biggest cable maker said on Thursday, as it predicted 2024 results at the upper end of its estimates. Milan-based Prysmian last month announced the $4.2 billion acquisition of Encore Wire to expand in its North American profit powerhouse. Chief Executive Massimo Battaini told analysts the process was going well and no major issues were expected.